CL2011003205A1 - Compuesto 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)-etil]-[1,2,4]triazolo[1,5-a]pirazina; composicion farmaceutica; y su uso para el tratamiento de un trastorno neurodegenerativo, tales como alzheimer y demencias. - Google Patents
Compuesto 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)-etil]-[1,2,4]triazolo[1,5-a]pirazina; composicion farmaceutica; y su uso para el tratamiento de un trastorno neurodegenerativo, tales como alzheimer y demencias.Info
- Publication number
- CL2011003205A1 CL2011003205A1 CL2011003205A CL2011003205A CL2011003205A1 CL 2011003205 A1 CL2011003205 A1 CL 2011003205A1 CL 2011003205 A CL2011003205 A CL 2011003205A CL 2011003205 A CL2011003205 A CL 2011003205A CL 2011003205 A1 CL2011003205 A1 CL 2011003205A1
- Authority
- CL
- Chile
- Prior art keywords
- disorder
- disease
- compound
- alzheimer
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- NBKCQLCLNHGTJU-UHFFFAOYSA-N 5,8-dimethyl-2-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound N=1N2C(C)=CN=C(C)C2=NC=1CCC(N(C=1)C)=NC=1C1=CC=CC=C1 NBKCQLCLNHGTJU-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 208000020358 Learning disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 201000003723 learning disability Diseases 0.000 abstract 2
- 208000022821 personality disease Diseases 0.000 abstract 2
- 206010065040 AIDS dementia complex Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010012218 Delirium Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000036626 Mental retardation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000022372 Reading disease Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 230000003109 amnesic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010013932 dyslexia Diseases 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 238000007917 intracranial administration Methods 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
CANTIDAD TERAPÉUTICAMENTE EFICAZ DE DICHO COMPUESTO Y UNO O MÁS PORTADORES, DILUYENTES Y EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES. USO DE DICHO COMPUESTO PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE UN TRASTORNO<br /> NEURODEGENERATIVO O SIQUIÁTRICO, DONDE EL TRASTORNO NEURODEGENERATIVO SE SELECCIONA DEL GRUPO FORMADO POR<br /> LA ENFERMEDAD DE ALZHEIMER, DEMENCIA POR MÚLTIPLES INFARTOS, DEMENCIA ALCOHÓLICA U OTRA DEMENCIA RELACIONADA CON DROGAS, DEMENCIA ASOCIADA CON TUMORES INTRACRANEALES O TRAUMATISMO CEREBRAL, DEMENCIA ASOCIADA CON LA ENFERMEDAD DE HUNTINGTON O CON LA ENFERMEDAD DE PARKINSON, O DEMENCIA RELACIONADA CON<br /> EL SIDA; DELIRIO; TRASTORNO AMNÉSICO; TRASTORNO DE ESTRÉS POST-TRAUMÁTICO; RETRASO MENTAL; UN TRASTORNO, DEL APRENDIZAJE, TAL COMO, TRASTORNO DE LA LECTURA, TRASTORNO DEL APRENDIZAJE MATEMÁTICO O UN TRASTORNO DE EXPRESIÓN ESCRITA; TRASTORNO DE DÉFICIT ATENCIONAL/HIPERACTIVIDAD; Y DETERIORO COGNITIVO RELACIONADO CON LA EDAD, Y EL TRASTORNO SIQUIÁTRICO SE SELECCIONA DEL GRUPO FORMADO POR ESQUIZOFRENIA, TAL COMO DEL TIPO<br /> PARANOIDE, DESORGANIZADO, CATATÓNICO, NO DIFERENCIADO, O RESIDUAL; TRASTORNO DE LA PERSONALIDAD DEL TIPO PARANOIDE; Y TRASTORNO DE LA PERSONALIDAD DEL TIPO ESQUIZOIDE ENTRE OTROS.<br />
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200800855 | 2008-06-20 | ||
| DKPA200900402 | 2009-03-24 | ||
| DKPA200900519 | 2009-04-22 | ||
| PCT/DK2009/050134 WO2009152825A1 (en) | 2008-06-20 | 2009-06-19 | Novel phenylimidazole derivatives as pde10a enzyme inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011003205A1 true CL2011003205A1 (es) | 2012-06-22 |
Family
ID=40902594
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2010001467A CL2010001467A1 (es) | 2008-06-20 | 2010-12-17 | Compuestos derivados de fenil-imidazol sustituido con un heteroaromatico biciclico; composicion farmaceutica que los comprende; y su uso como inhibidores de la pde10a para tratar trastornos neurodegenerativos o psiquiatricos como alzheimer, demencia alcoholica, trastorno del aprendizaje, esquizofrenia, adiccion a las drogas. |
| CL2011003205A CL2011003205A1 (es) | 2008-06-20 | 2011-12-16 | Compuesto 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)-etil]-[1,2,4]triazolo[1,5-a]pirazina; composicion farmaceutica; y su uso para el tratamiento de un trastorno neurodegenerativo, tales como alzheimer y demencias. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2010001467A CL2010001467A1 (es) | 2008-06-20 | 2010-12-17 | Compuestos derivados de fenil-imidazol sustituido con un heteroaromatico biciclico; composicion farmaceutica que los comprende; y su uso como inhibidores de la pde10a para tratar trastornos neurodegenerativos o psiquiatricos como alzheimer, demencia alcoholica, trastorno del aprendizaje, esquizofrenia, adiccion a las drogas. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8841297B2 (es) |
| EP (1) | EP2318394B1 (es) |
| JP (1) | JP5930714B2 (es) |
| KR (3) | KR101703938B1 (es) |
| CN (2) | CN102124002B (es) |
| AR (1) | AR072199A1 (es) |
| AU (1) | AU2009259209B2 (es) |
| BR (1) | BRPI0915383B8 (es) |
| CA (1) | CA2728335C (es) |
| CL (2) | CL2010001467A1 (es) |
| CO (1) | CO6321263A2 (es) |
| CY (1) | CY1115001T1 (es) |
| DK (1) | DK2318394T3 (es) |
| EA (2) | EA018880B1 (es) |
| ES (1) | ES2456349T3 (es) |
| HR (1) | HRP20140232T1 (es) |
| IL (1) | IL209834A (es) |
| MX (1) | MX2010014136A (es) |
| MY (1) | MY152949A (es) |
| NZ (1) | NZ589926A (es) |
| PL (1) | PL2318394T3 (es) |
| PT (1) | PT2318394E (es) |
| RS (2) | RS53226B (es) |
| SI (1) | SI2318394T1 (es) |
| TW (1) | TWI501965B (es) |
| WO (1) | WO2009152825A1 (es) |
| ZA (1) | ZA201100109B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8133897B2 (en) | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| CA2765750A1 (en) * | 2009-06-19 | 2010-12-23 | H. Lundbeck A/S | Novel phenylimidazole derivative as pde10a enzyme inhibitor |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| KR101713453B1 (ko) | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| US8410117B2 (en) * | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| US8969349B2 (en) | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
| TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
| TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
| EP2602255B1 (en) | 2010-08-04 | 2017-04-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| US9029536B2 (en) * | 2010-08-04 | 2015-05-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| ES2539464T3 (es) * | 2010-11-10 | 2015-07-01 | H. Lundbeck A/S | Ligandos basados en el fenilimidazol radiomarcados |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| US8552045B2 (en) | 2010-11-19 | 2013-10-08 | H. Lundbeck A/S | Tricyclic imidazole compounds as PDE10 inhibitors |
| US8349824B2 (en) * | 2010-12-07 | 2013-01-08 | Hoffmann-La Roche Inc. | Triazolopyridine compounds |
| US8765760B2 (en) | 2011-01-11 | 2014-07-01 | Sunovion Pharmaceuticals, Inc. | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases |
| US9540379B2 (en) * | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| CA2827724A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| WO2013005798A1 (ja) * | 2011-07-06 | 2013-01-10 | 持田製薬株式会社 | 新規含窒素複素環誘導体 |
| WO2013045607A1 (en) | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
| WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
| TWI570124B (zh) | 2011-12-21 | 2017-02-11 | Ｈ 朗德貝克公司 | 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物 |
| WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| PE20142366A1 (es) * | 2012-05-30 | 2015-01-10 | Hoffmann La Roche | Compuestos triazolo como inhibidores de pde 10 |
| EP2861596B1 (en) | 2012-06-19 | 2019-03-20 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| WO2014100533A1 (en) | 2012-12-21 | 2014-06-26 | Bristol-Myers Squibb Company | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS |
| NZ708593A (en) * | 2013-02-27 | 2018-01-26 | Mochida Pharm Co Ltd | Novel pyrazole derivative |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| HUE057317T2 (hu) | 2014-04-23 | 2022-04-28 | Dart Neuroscience Llc | Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok |
| NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| PL408251A1 (pl) * | 2014-05-19 | 2015-11-23 | Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| TWI568737B (zh) * | 2014-11-05 | 2017-02-01 | 達特神經科學（開曼）有限責任公司 | 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物 |
| KR20170139074A (ko) | 2015-04-24 | 2017-12-18 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| BR112020013820A2 (pt) | 2018-11-06 | 2021-06-01 | H. Lundbeck A/S | inibidores de pde10a para tratamento de sintomas negativos e comprometimentos cognitivos em um paciente sofrendo de esquizofrenia |
| US20200140446A1 (en) | 2018-11-06 | 2020-05-07 | H. Lundbeck A/S | 5,8-dimethyl-2-[2-(1-methyl-4-phenyl-1h-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate |
| BR112020013697A2 (pt) | 2018-11-06 | 2020-12-01 | H. Lundbeck A/S | compostos para tratamento de sintomas negativos e comprometimentos cognitivos |
| CN110981813A (zh) * | 2019-12-19 | 2020-04-10 | 西安近代化学研究所 | 一种2-氰基-5-芳基-1h-咪唑类化合物的合成方法 |
| CN111100071A (zh) * | 2019-12-19 | 2020-05-05 | 西安近代化学研究所 | 一种合成2-氰基-5-芳基-1h-咪唑类化合物的方法 |
| US12544364B2 (en) | 2020-06-05 | 2026-02-10 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036840A (en) | 1972-06-07 | 1977-07-19 | Icn Pharmaceuticals | 2-Substituted-s-triazolo[1,5a]pyrimidines |
| DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
| RS20050945A (sr) * | 2003-06-30 | 2008-06-05 | Altana Pharma Ag., | Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera |
| EP1723134A2 (en) * | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| EP1722783A4 (en) | 2004-03-08 | 2009-08-12 | Wyeth Corp | MODULATORS OF THE ION CHANNEL FUNCTION |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| CA2643963A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| JP2009541481A (ja) | 2006-06-26 | 2009-11-26 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害剤としての三環式ヘテロアリール化合物 |
| EP2173728A2 (en) | 2007-07-17 | 2010-04-14 | Amgen Inc. | Heterocyclic modulators of pkb |
| CA2695989A1 (en) | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| US8133897B2 (en) | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| CA2765750A1 (en) | 2009-06-19 | 2010-12-23 | H. Lundbeck A/S | Novel phenylimidazole derivative as pde10a enzyme inhibitor |
-
2009
- 2009-06-15 TW TW098119876A patent/TWI501965B/zh not_active IP Right Cessation
- 2009-06-19 AR ARP090102239A patent/AR072199A1/es active IP Right Grant
- 2009-06-19 EA EA201170061A patent/EA018880B1/ru not_active IP Right Cessation
- 2009-06-19 AU AU2009259209A patent/AU2009259209B2/en not_active Ceased
- 2009-06-19 KR KR1020107028654A patent/KR101703938B1/ko not_active Expired - Fee Related
- 2009-06-19 CN CN200980132027.3A patent/CN102124002B/zh not_active Expired - Fee Related
- 2009-06-19 BR BRPI0915383A patent/BRPI0915383B8/pt not_active IP Right Cessation
- 2009-06-19 EP EP09765461.0A patent/EP2318394B1/en active Active
- 2009-06-19 CA CA2728335A patent/CA2728335C/en not_active Expired - Fee Related
- 2009-06-19 KR KR1020177034302A patent/KR102025487B1/ko not_active Expired - Fee Related
- 2009-06-19 MX MX2010014136A patent/MX2010014136A/es active IP Right Grant
- 2009-06-19 WO PCT/DK2009/050134 patent/WO2009152825A1/en not_active Ceased
- 2009-06-19 HR HRP20140232AT patent/HRP20140232T1/hr unknown
- 2009-06-19 DK DK09765461.0T patent/DK2318394T3/en active
- 2009-06-19 ES ES09765461.0T patent/ES2456349T3/es active Active
- 2009-06-19 PL PL09765461T patent/PL2318394T3/pl unknown
- 2009-06-19 MY MYPI20106011 patent/MY152949A/en unknown
- 2009-06-19 SI SI200930879T patent/SI2318394T1/sl unknown
- 2009-06-19 NZ NZ589926A patent/NZ589926A/en not_active IP Right Cessation
- 2009-06-19 PT PT97654610T patent/PT2318394E/pt unknown
- 2009-06-19 JP JP2011513878A patent/JP5930714B2/ja not_active Expired - Fee Related
- 2009-06-19 KR KR1020177002859A patent/KR20170016523A/ko not_active Ceased
- 2009-06-19 RS RS20140135A patent/RS53226B/sr unknown
-
2010
- 2010-06-17 US US13/378,405 patent/US8841297B2/en not_active Expired - Fee Related
- 2010-06-17 CN CN201080037331.2A patent/CN102482262B/zh not_active Expired - Fee Related
- 2010-06-17 RS RS20140700A patent/RS53704B1/sr unknown
- 2010-06-17 EA EA201270046A patent/EA021410B1/ru not_active IP Right Cessation
- 2010-12-07 IL IL209834A patent/IL209834A/en active IP Right Grant
- 2010-12-17 CL CL2010001467A patent/CL2010001467A1/es unknown
- 2010-12-20 CO CO10159483A patent/CO6321263A2/es active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00109A patent/ZA201100109B/en unknown
- 2011-12-16 CL CL2011003205A patent/CL2011003205A1/es unknown
-
2014
- 2014-03-28 CY CY20141100233T patent/CY1115001T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011003205A1 (es) | Compuesto 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)-etil]-[1,2,4]triazolo[1,5-a]pirazina; composicion farmaceutica; y su uso para el tratamiento de un trastorno neurodegenerativo, tales como alzheimer y demencias. | |
| ECSP18078877A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| CU20130107A7 (es) | IMIDAZO[5,1-f][1,2,4] TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS | |
| CL2010000129A1 (es) | Compuestos derivados de benzazepinas fusionadas sustituidas, moduladores del receptor de acetilcolina; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de trastornos del snc tales como esquizofrenia, demencia, enfermedad del alzheimer, esclerosis multiple, entre otras. | |
| ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
| MX2015011618A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso. | |
| ECSP19048477A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| CL2013002486A1 (es) | Compuestos derivados de 6,7-dihidropirazolo [1,5-a]pirazin-4-il-amina, inhibidores de beta - secretasa (bace); composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, senilidad, demencia, sindrome de down, entre otras. | |
| PE20091977A1 (es) | Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa-7 | |
| CR20130339A (es) | Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos | |
| CL2009000953A1 (es) | Compuestos derivados de 2-imino-3-metil-pirrolo pirimidinona, composicion farmaceutica, util para inhibir la beta-secretasa, destinado al tratamiento de la enfermedad de alzheimer, sindrome de down, parkinson, perdida de la memoria, demencia, accidente cerebrovascular, microgliosis e inflamacion cerebral, glaucoma amiloidosis, diabetes tipo ii, entre otras. | |
| BR112017022568A2 (pt) | compostos e seus usos como inibidores de bace1 | |
| WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
| MX2012010658A (es) | Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa. | |
| CL2020002820A1 (es) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina . | |
| CL2014003374A1 (es) | Sal del tipo camsilato de (1r,1' r,4r)-4-metoxi-5''-metil-6'-[5-(prop-1-in-1-il)piridin-3-il]-3'h-diespiro[ciclohexano-1,2'-inden-1' 2'-imidazol]-4''-amina; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento o prevencion de patologias tales como sindrome de down, enfermedad de alzheimer, perdida de memoria, demencia, entre otras. | |
| HRP20151273T1 (hr) | Heterocikliäśki spojevi fenoksilmetila | |
| MX2019007104A (es) | Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso. | |
| AR064739A1 (es) | Compuesto de [1,2,3] -benzotriazinona-3- sustituido para mejorar las respuestas sinapticas glutamatergicas | |
| EP3976804A4 (en) | SOX9-INDUCED OLIGODENDROCYTE PROGENITORS | |
| CL2012001092A1 (es) | Compuestos derivados de 1-oxo-2-aza-espirolo 4.5- dec-7-il -amida, moduladores del receptor de glutamato metabotropico 5( mglu5 o mglur5); composicion farmaceutica: utiles en el tratamiento de trastornos cognitivos, neurodegenerativos, psiquiatricos o neurologicos, tales como ansiedad, esquizofrenia, alzheimer, entre otros. | |
| CL2008002088A1 (es) | Compuestos derivados de fenilo sustituido, moduladores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos cognitivos tales como demencia, alzheimer, entre otros. | |
| AR079103A1 (es) | Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion | |
| ECSP10010397A (es) | Preparacion y separacion enantiomerica de 7-(3- piridinilo)-1,7-diazaspiro[4.4] nonano y formas novedosas de sal de la mezcla racemica y enantiomeros | |
| IN2014DN09826A (es) |